Global University Venturing: Covid-19 remains a threat but universities are at the forefront of fighting back

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

The testing services provider hiked its overall funding to more than $68m in a round backed by Alibaba Hong Kong Entrepreneurs Fund.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.

Tencent has led a $64m series D round for the healthtech developer, whose shareholders already include SoftBank.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.